Thomas Civik

Pyxis Oncology, Inc., a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, has appointed Thomas Civik as Chief Executive Officer (CEO) and Chairman of the Board. 

Civik has served as Interim CEO since February 2026 and has been a member of Pyxis Oncology’s Board since 2021.

Following Civik’s appointment as Chairman, John Flavin, co-founder and founding Chairman of Pyxis Oncology, will transition to Lead Independent Director while continuing to serve on the Board. Flavin has been involved in the company’s leadership since its founding and contributed to its development into a clinical-stage organization.

Civik brings extensive experience in the biopharmaceutical and oncology sectors. He most recently served as Chairman of ImCheck Therapeutics, which was acquired by Ipsen, and Repare Therapeutics, which was acquired by XOMA. Previously, he served as President and CEO of Five Prime Therapeutics until its acquisition by Amgen for $1.9 billion in April 2021.

Earlier in his career, Civik was Chief Commercial Officer at Foundation Medicine and spent 17 years at Genentech in various leadership roles. His responsibilities included commercial activities for therapies such as Avastin, Tecentriq, Alecensa and Tarceva.

Civik holds a Bachelor of Arts degree from St. Norbert College and an MBA from Northwestern University’s Kellogg School of Management.

Under its updated leadership, Pyxis Oncology expects to report data from its ongoing MICVO Phase 1 monotherapy study in second-line and later recurrent/metastatic head and neck squamous cell carcinoma in fall 2026. The company also expects to provide updated data from its Phase 1/2 combination study with pembrolizumab in first-line disease during the fourth quarter of 2026.